Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) and Pyxis Oncology (NASDAQ:PYXS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk.
Valuation & Earnings
This table compares Kiora Pharmaceuticals and Pyxis Oncology”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kiora Pharmaceuticals | $16.02 million | 0.45 | $3.60 million | ($2.09) | -0.94 |
| Pyxis Oncology | $16.15 million | 4.43 | -$77.33 million | ($1.60) | -0.72 |
Volatility and Risk
Kiora Pharmaceuticals has a beta of -0.89, suggesting that its stock price is 189% less volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Kiora Pharmaceuticals and Pyxis Oncology, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kiora Pharmaceuticals | 1 | 1 | 1 | 0 | 2.00 |
| Pyxis Oncology | 1 | 1 | 5 | 0 | 2.57 |
Kiora Pharmaceuticals presently has a consensus price target of $10.00, suggesting a potential upside of 407.61%. Pyxis Oncology has a consensus price target of $7.20, suggesting a potential upside of 526.09%. Given Pyxis Oncology’s stronger consensus rating and higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than Kiora Pharmaceuticals.
Institutional and Insider Ownership
77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 0.1% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 10.6% of Pyxis Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Kiora Pharmaceuticals and Pyxis Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kiora Pharmaceuticals | N/A | -36.35% | -25.82% |
| Pyxis Oncology | N/A | -84.70% | -61.72% |
Summary
Pyxis Oncology beats Kiora Pharmaceuticals on 9 of the 13 factors compared between the two stocks.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
About Pyxis Oncology
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Kiora Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiora Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
